List of Excipients in Branded Drug COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Noven Therapeutics LLC	COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)	estradiol/norethindrone acetate transdermal system	68968-0514	DIPROPYLENE GLYCOL
Noven Therapeutics LLC	COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)	estradiol/norethindrone acetate transdermal system	68968-0514	OLEIC ACID
Noven Therapeutics LLC	COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)	estradiol/norethindrone acetate transdermal system	68968-0514	POVIDONE K30

Last updated: August 21, 2026

ecutive summary: CombiPatch is a twice-weekly transdermal hormone-replacement product containing estradiol and norethindrone acetate. Its commercial value rests on co-delivery of two hormones through a single patch, stable skin adhesion, predictable release, and avoidance of oral first-pass metabolism. The strongest generic and licensing opportunities are likely to involve adhesive systems, drug-in-adhesive matrices, patch size, release control, manufacturing yield, and patient-friendly packaging rather than a new active-ingredient claim. Public FDA materials identify the product and its dosage form, but they do not provide a complete current patent-family, Orange Book, litigation, or commercial-revenue analysis.

CombiPatch Excipient Strategy and Commercial Opportunities

What is CombiPatch and how does its transdermal system work?

CombiPatch is a continuous combined hormone-replacement therapy containing estradiol and norethindrone acetate. It is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis in women with an intact uterus when other therapies are inappropriate or not tolerated.[1]

The product is applied twice weekly. Its delivery system is designed to release both active ingredients through the skin over the wear interval. The FDA prescribing information describes the patch as a multilayer transdermal system containing a backing layer, an adhesive drug matrix, and a release liner.[1]

Product attribute	CombiPatch profile
Active ingredients	Estradiol and norethindrone acetate
Dosage form	Transdermal system
Administration	Twice weekly
Original developer	Noven Pharmaceuticals
FDA application	NDA 020989
Therapeutic category	Menopausal hormone therapy
Primary commercial differentiator	Single patch delivering estrogen and progestin
Key formulation problem	Maintaining co-delivery, adhesion, skin tolerance, and dose uniformity

The active ingredients create different formulation demands. Estradiol is a potent, low-dose steroid suitable for transdermal delivery. Norethindrone acetate must also be released at a controlled rate while remaining compatible with the adhesive matrix and patch manufacturing process. The excipient system must support both compounds without causing crystallization, phase separation, excessive tack, skin irritation, or loss of adhesion during wear.

What excipients are used in CombiPatch?

Public labeling describes the product architecture but does not disclose every quantitative formulation parameter. The core excipient strategy is an adhesive matrix system rather than a conventional tablet-style excipient blend.[1]

Adhesive matrix

The adhesive matrix performs several functions:

• holds estradiol and norethindrone acetate in a uniform drug-containing layer;
• controls drug dissolution and diffusion;
• bonds the system to the skin;
• maintains contact over the prescribed wear period;
• supports removal without excessive residue or skin trauma.

For a commercial transdermal product, the adhesive is a critical performance excipient. A change in polymer grade, tackifier level, plasticizer, residual solvent, or coating weight can affect drug release and bioequivalence.

Potential adhesive families include acrylic, silicone, and polyisobutylene systems. A generic developer cannot assume interchangeability between them. Each system has a different balance of tack, cohesion, drug solubility, moisture response, crystallization risk, and skin compatibility.

Backing layer

The backing layer protects the drug matrix from environmental exposure and limits drug loss away from the skin. It must have suitable flexibility, chemical resistance, water-vapor behavior, and compatibility with the adhesive.

Backing-film selection has commercial relevance because film thickness and flexibility affect patient handling. A thinner patch may improve comfort, while a more robust film can reduce tearing and edge lift.

Release liner

The release liner protects the adhesive surface before application. It must separate cleanly without removing drug matrix material or leaving fragments on the patch. Release-liner treatment can materially affect manufacturing speed, packaging, and patient usability.

Packaging components

Individual pouch packaging protects the patch from oxygen, moisture, light, and premature adhesion to package surfaces. Packaging materials can influence shelf life and should be evaluated together with the matrix because steroid-containing adhesive systems may be sensitive to migration, solvent loss, and environmental exposure.

Which excipient attributes create the largest development opportunity?

The most valuable opportunities are excipient changes that improve a measurable product attribute without changing the therapeutic concept.

Excipient or component	Commercial objective	Key development risk
Acrylic adhesive	Lower cost and scalable coating	Drug crystallization and skin irritation
Silicone adhesive	Improved skin tolerance and clean removal	Lower drug loading or altered release
Polyisobutylene system	Strong cohesion and stable adhesion	Difficult processing and residue
Tackifier	Better initial adhesion	Irritation, migration, and release impact
Plasticizer	Improved flexibility and drug mobility	Loss of cohesion and accelerated release
Backing film	Better comfort and moisture control	Delamination or permeability changes
Release liner	Easier patient application	Matrix damage during removal
Pouch laminate	Longer shelf life	Higher packaging cost and recycling constraints

A commercially useful formulation program should prioritize adhesion retention, drug crystallization control, skin irritation, residual drug content, patch dimensions, and manufacturing throughput. These attributes often determine whether a product can achieve robust bioequivalence and acceptable commercial margins.

What formulations are protected by CombiPatch-related intellectual property?

The likely intellectual-property focus is the combination of:

1. estradiol and norethindrone acetate in one transdermal system;
2. a drug-in-adhesive matrix;
3. controlled delivery over a defined wear interval;
4. defined drug loading and patch area;
5. adhesive composition and coating process;
6. packaging and storage conditions;
7. methods of treating menopausal symptoms or preventing osteoporosis.

The active ingredients themselves are old and generally cannot provide meaningful new-molecule exclusivity. Commercial protection therefore depends on formulation, delivery-system, manufacturing, and method-of-use claims.

A complete patent analysis requires a current review of U.S. Patent and Trademark Office records, FDA Orange Book entries, international family members, terminal disclaimers, maintenance-fee status, and litigation databases. Public product labeling alone does not establish the current enforceability or expiration status of every patent related to CombiPatch.

What is the Orange Book status of CombiPatch?

CombiPatch is associated with FDA NDA 020989. The Orange Book is the controlling FDA source for listed patents and exclusivity associated with an approved drug application.[2]

For generic strategy, the relevant questions are:

• whether CombiPatch is listed as the reference listed drug;
• whether any formulation, method-of-use, or drug-delivery patents remain listed;
• whether listed patents are expired, delisted, or subject to certification;
• whether an ANDA applicant must submit a Paragraph IV certification;
• whether the reference sponsor has initiated litigation within the statutory period.

Patent status cannot be inferred from the product’s original approval date. A transdermal product may have later-issued patents covering adhesive systems, manufacturing methods, or specific dosage strengths.

When does CombiPatch lose exclusivity?

CombiPatch’s original FDA approval dates back to 1998, so new-drug exclusivity associated with the original application is no longer commercially relevant.[1] Any current barrier to generic entry would more likely arise from listed patents, regulatory requirements, manufacturing complexity, or market economics.

For a generic applicant, the practical entry sequence is:

1. identify the current reference listed drug;
2. review Orange Book patent listings;
3. determine whether a Paragraph IV certification is required;
4. establish in-vitro and clinical or pharmacokinetic bioequivalence;
5. demonstrate adhesion performance and product quality;
6. address any patent litigation;
7. obtain ANDA approval and launch after legal clearance or settlement.

Transdermal products can be more difficult to copy than oral dosage forms because equivalence depends on drug release, skin permeation, adhesion, residual drug, patch size, and manufacturing controls.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV challenge would target an Orange Book-listed patent as invalid, unenforceable, or not infringed. The commercial risk depends on the specific patent claims and the applicant’s design-around strategy.

Main generic risks

A generic CombiPatch applicant would face several technical risks:

• different adhesive chemistry may alter estradiol or norethindrone acetate flux;
• a different backing film may change moisture transmission;
• a different patch area may affect delivery rate;
• altered drug loading may create crystallization;
• adhesive residue may reduce patient acceptance;
• skin irritation may be higher than the reference product;
• manufacturing scale-up may produce coating-weight variability;
• release specifications may be difficult to match across the full shelf life.

The highest-value design-around opportunity is a matrix that delivers comparable systemic exposure while avoiding narrow composition claims. A developer may also seek claims directed to a specific adhesive, solvent-free coating process, multilayer arrangement, or improved stability profile.

How strong is the CombiPatch patent estate?

The apparent strength of the estate is mixed.

Patent category	Likely strength
Active-ingredient composition	Low, because both hormones are established compounds
Original combination concept	Low to moderate, depending on remaining claim scope
Transdermal delivery system	Moderate
Adhesive composition	Moderate to high if narrowly claimed and technically supported
Manufacturing process	Moderate if process-specific and difficult to design around
Method of use	Variable and potentially limited by prior art
Packaging and stability	Moderate, but often narrow
Device or patch architecture	Moderate where performance depends on structure

Formulation patents are strongest when they link composition to a demonstrated technical result, such as stable release, reduced crystallization, improved adhesion, or lower irritation. Broad claims covering any adhesive patch containing estradiol and norethindrone acetate are more vulnerable to prior-art and obviousness challenges.

What licensing opportunities exist for CombiPatch technology?

Licensing opportunities fall into four categories.

Generic or authorized-generic commercialization

A company with an approved or near-approval transdermal platform could seek a supply, licensing, or authorized-generic arrangement with the reference sponsor. The value would depend on whether the agreement provides access to manufacturing know-how, regulatory files, trademarks, or distribution rights.

Adhesive-platform licensing

An excipient or transdermal technology company could license an adhesive matrix that provides:

• lower skin irritation;
• better adhesion in heat and humidity;
• reduced edge lift;
• low residue after removal;
• improved drug loading;
• solvent-free manufacturing.

The most defensible licensing package would combine composition claims with process controls and comparative performance data.

Manufacturing partnerships

Contract development and manufacturing organizations with continuous coating, slitting, pouching, and serialization capabilities may have an advantage. Transdermal manufacturing requires specialized coating equipment and environmental controls, creating a barrier that does not exist for many oral generics.

International commercialization

The commercial opportunity differs by jurisdiction. Patent, regulatory, reimbursement, and substitution rules vary across the United States, Europe, Canada, Japan, and emerging markets. A company may pursue regional rights where menopausal hormone therapy has established reimbursement and where local transdermal manufacturing capacity is limited.

How does CombiPatch compare with competing hormone-replacement products?

CombiPatch competes with oral combined hormone therapies, separate estradiol and progestin products, estrogen-only patches, and other combined transdermal systems.

Product strategy	Commercial advantage	Limitation
CombiPatch-style combined patch	One product and twice-weekly dosing	Complex co-delivery formulation
Separate estradiol patch plus oral progestin	Flexible dose adjustment	More complicated regimen
Oral estrogen/progestin	Familiar administration and broad availability	First-pass metabolism and systemic tolerability concerns
Estradiol-only patch	Strong estrogen delivery platform	Requires separate endometrial protection in women with a uterus
New combined transdermal system	Opportunity for improved comfort or dosing	Requires costly development and equivalence work

A new product could differentiate through once-weekly dosing, smaller patch size, lower residue, improved adhesion during exercise or bathing, or a more discreet appearance. Any new formulation must preserve adequate progestin exposure because insufficient endometrial protection is a material clinical and regulatory risk.

What FDA regulatory requirements apply to a new CombiPatch competitor?

An ANDA applicant must generally demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For transdermal systems, FDA evaluation can include:

• sameness of active ingredients;
• dosage form and route;
• strength;
• patch dimensions;
• drug content and release;
• adhesion and irritation;
• residual drug;
• in-vitro release testing;
• pharmacokinetic studies;
• stability and packaging;
• manufacturing process controls.

A 505(b)(2) application may be appropriate where the product differs materially from the reference system, such as through a new delivery technology, different patch design, or modified dosing interval. That pathway can support differentiated claims but usually requires a larger clinical and regulatory package than a conventional ANDA.

What commercial opportunities exist in the CombiPatch market?

The strongest opportunities are product improvements with direct patient or payer value:

1. a lower-cost generic with reliable adhesion;
2. a smaller or thinner patch;
3. a lower-irritation adhesive system;
4. a once-weekly combined patch;
5. packaging that improves opening and application;
6. a formulation with reduced drug crystallization;
7. regional licensing for markets with limited transdermal competition;
8. contract manufacturing for hormone-replacement patches.

Revenue exposure should be modeled from prescription volume, net price, generic erosion, reimbursement, and product availability. Public FDA materials do not establish current CombiPatch revenue, market share, or net pricing. Any investment analysis should separate branded sales, authorized-generic sales, and third-party generic sales.

What manufacturing and intellectual-property barriers affect entry?

Manufacturing is a substantial barrier. Critical operations include drug dissolution, adhesive compounding, precision coating, drying, lamination, die-cutting, pouching, and inspection. Small deviations in coating weight or drug distribution can affect dose uniformity and release.

The principal IP barriers are likely to involve:

• adhesive compositions;
• drug solubilization;
• matrix structure;
• release-rate control;
• patch dimensions;
• coating and drying conditions;
• packaging configurations;
• stability improvements;
• methods of reducing skin irritation.

A viable entrant should use a claim chart linking every proposed formulation element to published patents, pending applications, expired patents, and prior-art references. Freedom-to-operate analysis should cover the United States and all intended launch markets.

Key takeaways

• CombiPatch is a twice-weekly estradiol/norethindrone acetate transdermal system associated with FDA NDA 020989.
• Its commercial differentiation comes from combined hormone delivery through a single adhesive patch.
• The most important excipients are those controlling adhesion, drug solubility, release, skin tolerance, and stability.
• The active ingredients provide little current exclusivity value; formulation, manufacturing, and delivery-system claims are more relevant.
• Generic entry is technically harder than for an oral product because adhesion, release, permeation, residual drug, and skin response must be controlled.
• The strongest commercial opportunities involve lower-cost manufacturing, improved adhesion, reduced irritation, smaller patch size, improved packaging, or longer wear time.
• Current patent expiration, Orange Book listing, Paragraph IV activity, litigation, settlement status, and revenue exposure require a live patent and regulatory record review.

FAQs

Can a different adhesive support a generic CombiPatch product?

Yes. A different adhesive may be viable if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, release, adhesion, irritation, stability, and manufacturing consistency.

Is a once-weekly CombiPatch formulation commercially attractive?

Yes, because reduced application frequency could improve adherence. It would likely require a 505(b)(2) or other non-ANDA development strategy if the dosing interval, patch architecture, or release profile differs materially from the reference product.

Are excipients in a transdermal patch patentable?

Yes. Adhesive polymers, solvent systems, drug-solubilization systems, multilayer structures, coating processes, and stability-enhancing compositions can be patented when the claims meet novelty, nonobviousness, written-description, and enablement requirements.

Does CombiPatch have biosimilar risk?

No. CombiPatch contains small-molecule steroid hormones, not a biologic. Competitive risk comes from generic or 505(b)(2) transdermal products, not biosimilars.

What is the main technical failure mode for a CombiPatch competitor?

The most consequential failure modes are inadequate adhesion, altered transdermal flux, drug crystallization, dose nonuniformity, skin irritation, and stability loss during storage.

References

1. U.S. Food and Drug Administration. (2023). CombiPatch: Estradiol/norethindrone acetate transdermal system prescribing information. Noven Pharmaceuticals, Inc.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.